- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/74 - Complexe majeur d'histocompatibilité [MHC]
Détention brevets de la classe C07K 14/74
Brevets de cette classe: 2080
Historique des publications depuis 10 ans
|
105
|
124
|
189
|
250
|
250
|
298
|
262
|
219
|
171
|
86
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Immatics Biotechnologies GmbH | 1127 |
523 |
| Cue Biopharma, Inc. | 205 |
106 |
| Regeneron Pharmaceuticals, Inc. | 4873 |
68 |
| CRISPR Therapeutics AG | 373 |
54 |
| University Health Network | 1071 |
38 |
| 10X Genomics, Inc. | 1391 |
23 |
| Universite de Montreal | 346 |
22 |
| Board of Regents, The University of Texas System | 6187 |
20 |
| The Regents of the University of California | 20960 |
19 |
| Sana Biotechnology, Inc. | 185 |
15 |
| Ecole Polytechnique Federale de Lausanne (epfl) | 1627 |
14 |
| Imcyse SA | 60 |
14 |
| Oregon Health & Science University | 756 |
14 |
| Dana-Farber Cancer Institute, Inc. | 2681 |
13 |
| Sangamo Therapeutics, Inc. | 383 |
13 |
| Inscripta, Inc., FORMERLY Muse Biotechnology, Inc. | 268 |
13 |
| UTi Limited Partnership | 466 |
12 |
| Xyphos Biosciences Inc. | 35 |
12 |
| Immunocore Limited | 248 |
11 |
| Massachusetts Institute of Technology | 10322 |
10 |
| Autres propriétaires | 1066 |